Open Innovation Corporate Venture Capital M&A Strategy Portfolio Strategy Licensing External Capital Deployment BD

AbbVie, Big Pharma, Pharma M&A, BD&L, Corporate Venture Capital, Patent Cliff, Capital Allocation

The $85 Billion shopping spree: How AbbVie bought, borrowed and built its way out of a Humira cliff

A complete strategic breakdown of AbbVie’s playbook on how it engineered its way out of the Humira patent cliff, analyzing M&A capital flows, pipeline risks, and therapeutic market positioning.

archive-july-2026

Mercks & Co's sprint against the KEYTRUDA patent cliff: will it cross the finish line?

Merck quietly became one of the most aggressive external innovation buyers in the industry. But when your entire strategy hinges on replacing a $25B drug before the patent clock runs out, is buying your pipeline fast enough? Read the mechanics of what Merck & Co is doing to avoid the fall.

Novo Nordisk Akero Therapeutics Embark Biotech Catalent

Novo Nordisk: what will come out from the shopping bag of 100 year old Insulin Maker?

Novo Nordisk deployed billions in obesity and diabetes bets since 2023. Did they allocate capital to the right stage and modality? Read the analysis deal by deal to reveal the truth.